Quantitative and Standardized Pseudovirus Neutralization Assay for COVID-19

Published

April 1, 2024

Author(s)

Jerilyn Izac, Edward Kwee, Adolfas Gaigalas, Lili Wang

Abstract

COVID-19 is a global pandemic caused by the highly infectious SARS-CoV-2 virus. Efforts to combat SARS-CoV-2 infection include mass vaccination and development of monoclonal and convalescent plasma therapeutics that require precise measurements of correlative, functional neutralizing antibodies that prevent virus infection. Developing rapid, safe, easy-to-use, and high-quality neutralization assays are essential for the success of the massive effort. Here, we developed a vesicular stomatitis virus-based neutralization assay that was capable of quantifying varying degrees of neutralization in patient serum samples. This assay has two detection readouts, flow cytometry and live cell imaging. The two readout methods produced consistent values of all 50% neutralization titers, further enhancing measurement confidence on the assay. Moreover, the use of available reference standards such as WHO IS enables quantification and standardization of the pseudovirus neutralization assay with neutralizing antibody titers measured in the unit of IU/mL. Quantitative and standardized neutralization assays are critical for reliable efficacy evaluation and comparison of numerous vaccines and therapeutics.

Citation

Flow Cytometry Protocols, 5th Edition

Publisher Info

Humana Press/Springer, Totowa, NJ

Pub Type

Books

Download Paper

https://doi.org/10.1007/978-1-0716-3738-8_11

Local Download

Citation

Izac, J. , Kwee, E. , Gaigalas, A. and Wang, L. (2024), Quantitative and Standardized Pseudovirus Neutralization Assay for COVID-19, Humana Press/Springer, Totowa, NJ, [online], https://doi.org/10.1007/978-1-0716-3738-8_11, https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=956266 (Accessed January 13, 2025)